Bespoke ExtractsBSPK 22 Receivables Turnover is 4.57 as of Sep. 2025. GuruFocus rates BSPK with a GF Score™ of 22/100 and a GF Value™ of $0.22 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 947 Drug Manufacturers companies, Bespoke Extracts ranks better than 95.14% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Bespoke Extracts's Revenue for the
three
months ended in Sep. 2025 was $0.47 Mil. Bespoke Extracts's average Accounts Receivable for the
three
months ended in Sep. 2025 was $0.10 Mil.
Hence, Bespoke Extracts's Receivables Turnover for the
three
months ended in Sep. 2025 was 4.57.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Bespoke Extracts Receivables Turnover Related Terms
Bespoke Extracts Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Bespoke Extracts's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSPK vs IMCC, NPHC, SKYI: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bespoke Extracts's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bespoke Extracts Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bespoke Extracts's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Bespoke Extracts's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bespoke Extracts (BSPK) has a Receivables Turnover of 4.57 as of Sep. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bespoke Extracts and its competitors. According to the industry distribution chart, Bespoke Extracts ranks #46 out of 947 companies in the Drug Manufacturers industry, placing it in the top 4.9%.
Is Bespoke Extracts' Receivables Turnover too high?
Bespoke Extracts' current Receivables Turnover is 4.57. The Drug Manufacturers industry median Receivables Turnover is 5.07. Bespoke Extracts' value of 4.57 is 9.9% below this industry median. Based on the distribution chart, Bespoke Extracts ranks #46 out of 947 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bespoke Extracts has a GF Score™ of 22/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bespoke Extracts' Receivables Turnover compare to IMCC and NPHC?
According to the Drug Manufacturers industry distribution chart, Bespoke Extracts ranks #46 out of 947 companies for Receivables Turnover. This places Bespoke Extracts in the top 5% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. Bespoke Extracts' value of 4.57 is 9.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bespoke Extracts's current Receivables Turnover of 4.57 is 9.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bespoke Extracts and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bespoke Extracts's current Receivables Turnover is 4.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bespoke Extracts stock overvalued right now?
Based on GuruFocus' analysis, Bespoke Extracts (BSPK) is currently considered Possible Value Trap. The stock's GF Value™ is $0.22, compared to a current price of $0.12 — trading 45.3% below its estimated fair value. The current Receivables Turnover is 4.57 and 9.9% below the Drug Manufacturers industry median of 5.07. Bespoke Extracts' overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Bespoke Extracts (BSPK), the current Receivables Turnover is 4.57 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bespoke Extracts (BSPK) Overvalued in 2026?
Based on GuruFocus' analysis, Bespoke Extracts stock appears to be undervalued.
The current stock price of $0.12 is trading 45.3% below its estimated GF Value™ of $0.22.
GuruFocus considers Bespoke Extracts to be Possible Value Trap.
Key valuation signals for BSPK:
Receivables Turnover: 4.57
GF Value™: $0.22 vs. price of $0.12 (45.3% below fair value)
Industry Position: 9.9% below the Drug Manufacturers median (#46 of 947)
No single metric tells the full story. See the BSPK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bespoke Extracts Inc is focused on selling its proprietary line of specially-formulated, quality, hemp-derived CBD products. The company owns, manufactures, and distributes a portfolio of cannabis consumer packaged goods brands including Fresh Joints, Doobskis, DutchBlunts, and Wee Joints, to licensed marijuana dispensaries across Colorado.
22GF Score
Get the complete analysis for BSPK
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSPK has been successfully added to your 
